Skip to content

Exercise during CHemotherapy for Recurrent Ovarian cancer (ECHO-R)

A Phase II trial evaluating feasibility, safety and efficacy of an individually-tailored exercise intervention during chemotherapy for recurrent ovarian cancer (ECHO-R)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12621000042842
Acronym
ECHO-R
Enrollment
50
Registered
2021-01-18
Start date
2021-02-26
Completion date
2023-05-11
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study is aiming to evaluate the feasibility, safety and potential benefits of an individually tailored exercise intervention during chemotherapy for patients with recurrent Ovarian, Primary Peritoneal or Fallopian Tube cancer. Who is it for? You may be eligible for this study if you are 18 years or older, have been diagnosed with recurrent ovarian, peritoneal or fallopian tube cancer of all types, have had a platinum-free interval of at least 6 months (platinum-sensitive disease) and are scheduled to receive, or are currently receiving, chemotherapy (of any type). Study details All women who agree to join the study will participate in an individually tailored, home-based, 26-week exercise program throughout their chemotherapy treatment. Every participant will be allocated an Exercise Professional (who is trained in prescribing exercise to women with ovarian cancer). Participants will have regular phone/telehealth contact with their exercise professional as they support and encourage you to exercise during your chemotherapy. They will work with you to develop a program that can accommodate any ‘good’ and ‘bad’ days you may have during treatment, with the program tailored to meet your individual needs. This takes into consideration your fitness level, the types of activity you prefer to do and potential treatment-related side-effects you may experience. It may also be possible for participants to receive five face to face exercise sessions either at your home or another location suitable to you. If you live in the Brisbane area, these sessions may be carried out by your allocated Exercise Professional. For women who live outside of the Brisbane area we will arrange for these sessions to be carried out by a local Accredited Exercise Physiologist or Physiotherapist, whenever possible. It is hoped this research will determine the safety and usefulness of an individualised exercise program for cancer patients undergoing chemotherapy for recurrent ovarian cancer, which may lead to benefits for future cancer patients.

Interventions

Exercise intervention: The intervention will span 6 months and involve the individual prescription of aerobic and resistance-based exercise, with a dosage target of at least 150 minutes per week at moderate-intensity (moderate intensity = RPE of 11-13 on Borg RPE 6-20 scale). Examples of exercises that are likely to be prescribed include: aerobic exercise - walking, cycling, cycle/rowing ergometers, aerobics; resistance exercise - sessions focussing on major muscle groups, utilising bodyweight,

Exercise intervention: The intervention will span 6 months and involve the individual prescription of aerobic and resistance-based exercise, with a dosage target of at least 150 minutes per week at moderate-intensity (moderate intensity = RPE of 11-13 on Borg RPE 6-20 scale). Examples of exercises that are likely to be prescribed include: aerobic exercise - walking, cycling, cycle/rowing ergometers, aerobics; resistance exercise - sessions focussing on major muscle groups, utilising bodyweight, free weights, exercise bands and/or gym equipment (e.g., sit-to-stands, barbell chest press, exercise-band shoulder press, cable row). The location of prescribed exercise (e.g., home-based, local neighbourhood/ parks, gym) will depend on what is appropriate and preferred by each participant. An Exercise Professional (ExP; undergraduate training in exercise science) with study-specific prescription training will prescribe and monitor exercise type, duration and frequency on a regular basis and modify prescription according to the presentation of symptoms and by adhering to the exercise principle of gradual progression. Across the 6-month intervention, approximately 12 telephone/video-health exercise sessions between participants and their allocated ExP will be scheduled, with an average duration of each contact being approximately 60 minutes. The foundation intervention schedule is as follows: weeks 1 to 4 - once per week (4 sessions) weeks 5 to 16 - once per fortnight (6 sessions) weeks 17 to 26 – one per month (2-3 sessions) In the context of this pragmatic trial, women experiencing difficulty adhering to the prescribed exercise dose will be provided with more telehealth sessions (maximum number of sessions: 20 sessions). Less frequent contact may occur for those adhering to their exercise prescription and for whom weekly contact is therefore unnecessary or burdensome to the participant (minimum number of sessions: 8). When possible and when participants approve, the telehealth intervention will be supported by 5 face-to face visits with an exercise professional scheduled throughout the intervention (this intervention feature aligns with Australia’s Chronic Disease Management Plan, which allows for up to 5 reimbursable visits per year with an accredited Exercise Physiologist or Physiotherapist. Duration of these sessions will be approximately 60 minutes). These visits will occur at a location convenient to the participant (e.g., local park or exercise clinic; participant's home) Intervention adherence (i.e., participant attendance at scheduled sessions), fidelity (i.e., quality of delivery: exercise prescribed by ExPs; delivered dose: exercise completed by participants) will be assessed by the senior exercise physiologist (>10 years clinical experience) via monthly review of ExP session notes and patient-reported exercise doses. Participants struggling to adhere to the intervention schedule or exercise dosage will be offered modified contact with the ExP.

Sponsors

Griffith University
Lead SponsorUniversity

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Women with recurrent ovarian, peritoneal or fallopian tube cancer of all types (including epithelial, germ cell, stromal, granulosa cell) and a platinum-free interval of at least 6 months (platinum-sensitive disease) 2. Scheduled to receive, or currently receiving, chemotherapy (of any type). 3. Age 18 years or over 4. Willing and able to comply with all study requirements, including the exercise intervention, timing and nature of required assessments (note: face to face assessment is dependant on factors including timing and location, and does not constitute an exclusion criteria). 5. Sufficiently fluent in English to fully participate in data collection requirements and comprehend intervention requirements 6. Signed written informed consent

Exclusion criteria

Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol. NOTE: Since exercise safety has been demonstrated in a range of chronic disease settings such as cardiovascular disease, osteoarthritis and stroke, and the intervention is tailored to each woman’s capacity, the presence of other co-morbidities will NOT preclude participation if all other eligibility criteria are met.

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 14, 2026